

**PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) INTRACYCLE MEETING AGENDA
DECEMBER 2024 PBAC INTRACYCLE MEETING**

Please note that items in this agenda are subject to change at short notice.

PBAC Intracycle meetings are held between the main PBAC meetings. Submission items considered by the PBAC at these meetings typically relate to matters arising from previous submissions (e.g. items deferred) but can also relate to new medicines or applications that were held over from a previous meeting.

Consumers have the opportunity to provide comments on new medicine submissions if this opportunity has not been provided previously. Consumer comments already received, such as those in relation to medicines subject to a resubmission or those that have been held over from a previous meeting have been retained and will be considered.

Please note that all items included in this agenda are subject to change at short notice and, when possible, an updated agenda will promptly be published.

Pharmaceutical benefits listed in the Schedule fall into three broad categories:

Unrestricted benefits – have no restrictions on their therapeutic uses;

Restricted benefits – can only be prescribed for specific therapeutic uses (noted as Restricted benefit); and

Authority required benefits – Authority required benefits fall into two categories:

- *Authority required benefits* require prior approval from Services Australia or the DVA (noted as Authority required)
- *Authority required (STREAMLINED) benefits* do not require prior approval from Services Australia or the DVA but require the recording of a streamlined authority code (noted as Authority required (STREAMLINED)).

Resubmissions are categorised broadly as Standard Re-entry Pathway, Early Resolution Pathway, Early Re-entry Pathway or Facilitated Resolution Pathway. Submission categories and resubmission pathways are outlined in the [Procedure Guidance](#).

**PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) INTRACYCLE MEETING AGENDA
DECEMBER 2024 PBAC INTRACYCLE MEETING**

Please note that items in this agenda are subject to change at short notice.

Drug Name, form(s), strength(s), Sponsor, Submission type (Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing)	Drug Type and Use (What is the drug used to treat?)	Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.)
<p align="center">ARIPIPRAZOLE</p> <p>I.M. injection (modified release) 720 mg in 2.4 mL pre-filled syringe, I.M. injection (modified release) 960 mg in 3.2 mL pre-filled syringe</p> <p align="center">Abilify Asimtufii®</p> <p align="center">Lundbeck Australia Pty Ltd</p> <p align="center">(New listing)</p>	<p align="center">Long acting injectable form of aripiprazole for schizophrenia</p>	<p align="center">To request a General Schedule Authority Required (STREAMLINED) listing for the maintenance treatment of schizophrenia.</p>
<p align="center">ESKETAMINE</p> <p>Nasal spray solution 28 mg in 0.2 mL (2 actuations)</p> <p align="center">Spravato</p> <p align="center">JANSSEN-CILAG PTY LTD</p> <p align="center">(Matters Outstanding)</p>	<p align="center">Treatment resistant depression</p>	<p align="center">Deferred resubmission to request a Section 100 (Highly Specialised Drug Program) Authority Required (Telephone/Online) listing for the treatment of treatment resistant depression.</p>

**PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) INTRACYCLE MEETING AGENDA
DECEMBER 2024 PBAC INTRACYCLE MEETING**

Please note that items in this agenda are subject to change at short notice.

<p align="center">Drug Name, form(s), strength(s), Sponsor, Submission type (Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing)</p>	<p align="center">Drug Type and Use (What is the drug used to treat?)</p>	<p align="center">Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.)</p>
<p align="center">NIVOLUMAB</p> <p>Injection concentrate for I.V. infusion 40 mg in 4 mL Injection concentrate for I.V. infusion 100 mg in 10 mL</p> <p align="center">Opdivo</p> <p align="center">BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD</p> <p align="center">(Change to recommended listing)</p>	<p align="center">Non-small cell lung cancer (NSCLC)</p>	<p align="center">To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the perioperative treatment of NSCLC.</p>
<p align="center">Utilisation analysis of antihypertensives</p> <p align="center">Multiple strengths</p> <p align="center">Multiple brands</p> <p align="center">Multiple sponsors</p> <p align="center">(PBS review)</p>	<p align="center">Hypertension</p>	<p align="center">To provide the PBAC with a utilisation analysis of PBS-listed antihypertensives and to request that the PBAC consider the appropriateness of the current PBS restrictions for antihypertensive fixed dose combinations.</p>